![DiaMedica Therapeutics Inc](/common/images/company/N_DMAC.png)
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pip... DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1. Show more
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered...
Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 Key Proof-of-Concept Results Expected in the First Half of 2025 Management will Host a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 2.29 | 3.24 | 2.14 | 267491 | 2.9194595 | CS |
4 | 0 | 0 | 2.83 | 3.24 | 2.14 | 88399 | 2.83582427 | CS |
12 | 0 | 0 | 2.95 | 3.73 | 2.14 | 54506 | 2.90332313 | CS |
26 | 0 | 0 | 2.85 | 3.73 | 2.14 | 47268 | 2.89466127 | CS |
52 | 0 | 0 | 4.36 | 4.5 | 1.9382 | 64524 | 3.03250483 | CS |
156 | 0 | 0 | 7.29 | 7.35 | 1.12 | 106003 | 3.14572812 | CS |
260 | 0 | 0 | 4.62 | 10.88 | 1.12 | 98713 | 4.34769248 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.